WASHINGTON — Innovation in health care treatments and drug development is prompting calls for U.S. policy to contend with the biotech sector's growth, said regulators, advocates and investors at an ...

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

Endpoints News, the biopharma industry’s source for breaking news, exclusive reporting and smart analysis, today unveiled ...

Immunovant shares were on track for their worst session in over a year after the biotech said it was halting development of ...

Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

The company's stock rose to a 52-week high of $9.35 on Wednesday. Last week, the company introduced the Fill-Tek Dispensing System for essential custom reagents, designed to ease bioprocessing ...

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI ...